CellGenix® rh IL-6
GMP and Preclinical grade
CellGenix Recombinant Human IL-6 reliably stimulates the maturation of immature to mature dendritic cells (DCs) and promotes the proliferation of cord blood derived hematopoietic stem cells (HSCs/CD133+ cells). It is produced in our dedicated animal-free facility ensuring maximum safety for optimal use in ATMP manufacturing.
Interleukin-6 (IL-6) is a multifunctional cytokine that acts both pro-inflammatory and anti-inflammatory. It regulates acute phase responses, inflammatory reactions, hematopoiesis, bone metabolism, cancer progression and immune responses. It is produced primarily by T cells, monocytes and macrophages.
IL-6 is used in the cell and gene therapy space for the ex vivo maturation of immature DCs and proliferation of HSCs.
CellGenix Recombinant Human IL-6 is produced following all applicable GMP guidelines and allows for the safe use in accordance with USP Chapter <1043> and Ph. Eur. General Chapter 5.2.12.
Our GMP cytokines are provided with documented evidence of purity, potency, consistency and stability. In combination with our expert regulatory and technical support this will help simplify your raw material qualification and validation efforts.
CellGenix® Recombinant Human Interleukin-6
CellGenix® GMP rh IL-6
CellGenix® Preclinical rh IL-6
CellGenix® rh IL-6
- Produced in our dedicated animal-free facility
- Compliant to USP Chapter <1043> and Ph. Eur. General Chapter 5.2.12 (GMP)
- FDA Drug Master File available (GMP)
GMP & Preclinical Grade
- Seamless transition from preclinical development to ATMP manufacturing
Highest GMP Quality Standard
- High lot-to-lot consistency – save time on revalidations
- Performance reliability – rely on consistent product performance
- Highest purity – ensure the safety of your ATMP
- Extremely low endotoxin levels – improve safety and reproducibility
- Expert regulatory & technical support – rely on experience
Read more about our GMP Quality
Safe │ GMP Compliant │ Reliable
Expressed in E. coli
Human IL-6, accession # P05231, Pro29-Met212
Lyophilized from a 0.2 µm-filtered solution containing 1.5 mM potassium phosphate, 8.1 mM sodium phosphate, 2.7 mM potassium chloride and 137 mM sodium chloride, pH 7.5
Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: Preclinical vs GMP
|Molecular weight||21.9 kDa||21.9 kDa|
|Purity||≥ 95% as determined by SDS-PAGE||≥ 97% as determined by SDS-PAGE|
|Activity||≥ 50 x 106 IU/mg, calibrated against NIBSC #89/548||80 – 250 x 106 IU/mg, calibrated against NIBSC #89/548|
Batch specific activity on CoA
|Endotoxin level||< 1000 EU/mg||≤ 50 EU/mg|
|Intended use||Intended for preclinical ex vivo use. Not intended for human in vivo application.||Intended for clinical ex vivo use. Not intended for human in vivo application.|
Recommended in sterile water to a final concentration of 250 µg/ml for 50 µg vials and for 1 mg vials. We recommend to not vortex the solution. The solution can be turbid, this however does not influence the activity.
Ambient temperature. Please refer to Technote to learn more about our shipment validation procedure.
Storage & Stability
Store lyophilized cytokine at -20°C to -80°C.
Store a 100 µg/ml reconstituted cytokine solution:
• 4 weeks at 2°C to 8°C under sterile conditions after reconstitution. Store in the original container.
• 4 months at -20°C to -80°C under sterile conditions after reconstitution. Store in 60 µl aliquots in polypropylene cryogenic vials.
Avoid repeated freeze/thaw cycles.
CellGenix GMP rh IL-6 has an activity of 80 – 250 × 106 IU/mg
The activity of GMP rh IL-6 was measured in a cell proliferation assay using the IL-6-dependent cell line B9. It was calibrated against the NIBSC #89/548.
You can find the batch specific activity on the certificate of analysis (CoA).
- 3′, 4′-Dimethoxyflavone and valproic acid promotes the proliferation of human hematopoietic stem cells.
Kaur, K. et al., 2013, Stem Cell Research & Therapy
- Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
Danull, J. et al., 2013, The Journal of Clinical Investigation
- Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy
Hansen, M. et al., 2013, Vaccine
- Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
Ridolfi, L. et al., 2013, Journal of Translational Medicine
- Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Vik-Mo, EO. et al., 2013, Cancer Immunology Immunotherapy
- The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
Pellegatta, S. et al., 2013, Oncoimmunology
- Validation of analytical methods in compliance with good manufacturing practice: a practical approach
Rustichelli, D. et al., 2013, Journal of Translational Medicine
- An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma
Nava, S. et al., 2012, PloS One
- A phase II study evaluating the safety and efficacy of an adenovirus-DLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma
Chia, WK. et al., 2012, Annals of Oncology
- Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
Spanholtz, J. et al., 2011, PloS One
- Dendritic cell-based vaccination of patients with advanced melanoma: update of clinical outcome
Ridolfi, L. et al., 2010, Clinical and Developmental Immunology
- Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients
Lesterhuis, WJ. et al., 2010, Anticancer Research